This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BASEL, Switzerland–(BUSINESS WIRE)–Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital healthtechnology and develop digital biomarkers for Parkinson’s disease.
The funding speaks to the global nature of pre-approval access and its increasing importance in the drugdevelopment process. “ Our mutual dedication to building new approaches to pharmaceuticaldrugdevelopment and patient care will help bring promising pre-approval medicine to patients around the world, faster and more equitably.
The increasing adoption of digital healthtechnologies, the growing importance of AI and ML, and the evolving regulatory landscape will continue to shape the deal landscape. Health insurance and digital health: Health insurers may acquire digital health companies to improve their offerings and better manage patient populations.
DUBLIN–(BUSINESS WIRE)–The “Growth Opportunities in Drug Discovery and Early Development Outsourcing Services” report has been added to ResearchAndMarkets.com’s offering. hike over 2022, with more than 6,100 molecules in active development.
In 2025, B2C2B models are poised to become increasingly prominent in healthcare, driven by several key factors: Digital Health Boom: The rapid growth of digital healthtechnologies, such as telehealth, wearable devices, and AI-powered diagnostics, is creating new opportunities for B2C2B companies to reach both patients and healthcare providers.
Elevating Global Patient Access to Clinical Trials through Revolutionary Collaboration and Advanced AI-Driven Technologies NEW YORK–(BUSINESS WIRE)– Massive Bio Inc.,
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content